JP2018500326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500326A5 JP2018500326A5 JP2017532088A JP2017532088A JP2018500326A5 JP 2018500326 A5 JP2018500326 A5 JP 2018500326A5 JP 2017532088 A JP2017532088 A JP 2017532088A JP 2017532088 A JP2017532088 A JP 2017532088A JP 2018500326 A5 JP2018500326 A5 JP 2018500326A5
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- item
- composition
- deficiency
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 122
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 35
- -1 2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl Chemical group 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 208000013200 Stress disease Diseases 0.000 claims description 17
- 230000036542 oxidative stress Effects 0.000 claims description 17
- 238000002411 thermogravimetry Methods 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 7
- 230000010370 hearing loss Effects 0.000 claims description 7
- 231100000888 hearing loss Toxicity 0.000 claims description 7
- 208000016354 hearing loss disease Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 6
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 6
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 5
- 206010011878 Deafness Diseases 0.000 claims description 5
- 206010061323 Optic neuropathy Diseases 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 208000020911 optic nerve disease Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 4
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 4
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 4
- 208000014844 Mitochondrial neurogastrointestinal encephalomyopathy Diseases 0.000 claims description 4
- 206010065271 Mitochondrial neurogastrointestinal encephalopathy Diseases 0.000 claims description 4
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 4
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 4
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- 208000036640 Asperger disease Diseases 0.000 claims description 2
- 201000006062 Asperger syndrome Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000012639 Balance disease Diseases 0.000 claims description 2
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims description 2
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims description 2
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims description 2
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims description 2
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000025069 Juvenile Huntington disease Diseases 0.000 claims description 2
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 2
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000035719 Maculopathy Diseases 0.000 claims description 2
- 206010059521 Methylmalonic aciduria Diseases 0.000 claims description 2
- 206010059396 Mitochondrial DNA depletion Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 208000013234 Pearson syndrome Diseases 0.000 claims description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 206010057430 Retinal injury Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010047571 Visual impairment Diseases 0.000 claims description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims description 2
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 201000003694 methylmalonic acidemia Diseases 0.000 claims description 2
- 201000007998 methylmalonic aciduria and homocystinuria type cblC Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 230000035806 respiratory chain Effects 0.000 claims description 2
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 238000001757 thermogravimetry curve Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XYFMDAJSEGGDKR-UHFFFAOYSA-N 2,3,5-trimethylcyclohexane-1,4-dione Chemical compound CC1CC(=O)C(C)C(C)C1=O XYFMDAJSEGGDKR-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- RHSWDAWJROMVBG-UHFFFAOYSA-N N-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound C(CCC)(=O)NC1=C(C(C(=C(C1=O)C)C)=O)C RHSWDAWJROMVBG-UHFFFAOYSA-N 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092743P | 2014-12-16 | 2014-12-16 | |
| US62/092,743 | 2014-12-16 | ||
| US201562133276P | 2015-03-13 | 2015-03-13 | |
| US62/133,276 | 2015-03-13 | ||
| PCT/US2015/066211 WO2016100579A1 (en) | 2014-12-16 | 2015-12-16 | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020039715A Division JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500326A JP2018500326A (ja) | 2018-01-11 |
| JP2018500326A5 true JP2018500326A5 (enExample) | 2019-01-31 |
| JP6810692B2 JP6810692B2 (ja) | 2021-01-06 |
Family
ID=55071223
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532088A Active JP6810692B2 (ja) | 2014-12-16 | 2015-12-16 | （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2020039715A Active JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2021146086A Active JP7277061B2 (ja) | 2014-12-16 | 2021-09-08 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2022094160A Active JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020039715A Active JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2021146086A Active JP7277061B2 (ja) | 2014-12-16 | 2021-09-08 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2022094160A Active JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10251847B2 (enExample) |
| EP (2) | EP4059922A1 (enExample) |
| JP (4) | JP6810692B2 (enExample) |
| KR (1) | KR102626895B1 (enExample) |
| CN (2) | CN107531616B (enExample) |
| AU (3) | AU2015364640B2 (enExample) |
| BR (1) | BR112017012988B1 (enExample) |
| CA (1) | CA2971252C (enExample) |
| DK (1) | DK3233786T3 (enExample) |
| ES (1) | ES2912585T3 (enExample) |
| HU (1) | HUE058877T2 (enExample) |
| IL (1) | IL252953A0 (enExample) |
| MX (2) | MX385049B (enExample) |
| NZ (1) | NZ733528A (enExample) |
| PL (1) | PL3233786T3 (enExample) |
| PT (1) | PT3233786T (enExample) |
| RU (1) | RU2770091C2 (enExample) |
| SG (2) | SG10202003299PA (enExample) |
| SI (1) | SI3233786T1 (enExample) |
| WO (1) | WO2016100579A1 (enExample) |
| ZA (1) | ZA201704639B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610152C (en) | 2005-06-01 | 2018-04-10 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP3018122B1 (en) | 2007-11-06 | 2018-10-10 | BioElectron Technology Corporation | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| CN102264730B (zh) | 2008-10-28 | 2016-04-13 | 爱迪生药物公司 | 用于生产生育三烯酚及衍生物的方法 |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| WO2016100579A1 (en) | 2014-12-16 | 2016-06-23 | Edison Pharmaceuticals, Inc., | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| CN113024369A (zh) | 2015-12-17 | 2021-06-25 | Ptc医疗公司 | 用于治疗氧化应急障碍的化合物 |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| JP7586815B2 (ja) | 2018-10-17 | 2024-11-19 | ピーティーシー セラピューティクス， インコーポレイテッド | α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| CN115066420B (zh) * | 2020-02-21 | 2024-12-10 | Ptc医疗公司 | 光学拆分的Trolox中间体和其制造方法 |
| CN118175991A (zh) | 2021-07-08 | 2024-06-11 | Ptc医疗公司 | 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物 |
| CN119866216A (zh) | 2022-09-12 | 2025-04-22 | Ptc医疗公司 | 悬浮用颗粒 |
| JPWO2024071372A1 (enExample) * | 2022-09-30 | 2024-04-04 | ||
| WO2025193975A1 (en) | 2024-03-13 | 2025-09-18 | Ptc Therapeutics, Inc. | Formulations for stabilizing dissolution of medicaments |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4026907A (en) | 1973-11-19 | 1977-05-31 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
| US4018799A (en) | 1973-11-19 | 1977-04-19 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
| JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| US5272180A (en) | 1987-07-29 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Cell proliferation inhibitor |
| US5348973A (en) * | 1990-10-09 | 1994-09-20 | Rhone-Poulenc Chimie | Resolution of hydroxychroman-2-carboxylic acid esters by enantiomeric hydrolysis |
| US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
| KR100264348B1 (ko) | 1994-12-28 | 2000-08-16 | 디르크 반테 | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 |
| AU6709896A (en) | 1995-08-21 | 1997-03-12 | Takeda Chemical Industries Ltd. | Quinone compound, its production and use |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| EP0915696B1 (en) | 1996-07-11 | 2002-05-29 | Takeda Chemical Industries, Ltd. | ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION |
| JP3093170B2 (ja) | 1996-09-19 | 2000-10-03 | 株式会社ジャパンエナジー | ヒドロキノン誘導体及びその医薬用途 |
| AU716992B2 (en) | 1996-09-19 | 2000-03-16 | Japan Energy Corporation | Hydroquinone derivative and pharmaceutical use thereof |
| JP3913329B2 (ja) * | 1997-09-11 | 2007-05-09 | 株式会社クラレ | （±）−クロマンカルボン酸の光学分割法 |
| FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| WO2002012221A1 (en) | 2000-08-03 | 2002-02-14 | Kuraray Co., Ltd. | Method for optical resolution of (±)-6-hydroxy-2,5,7,8-tetramethylcoumarone-2-carboxylic acid |
| CA2430415A1 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| US7119117B2 (en) | 2001-08-21 | 2006-10-10 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| EP1378753B1 (en) | 2002-07-01 | 2006-05-31 | Santhera Pharmaceuticals (Schweiz) GmbH | A screening method and compounds for treating Friedreich Ataxia |
| WO2004042353A2 (en) | 2002-10-30 | 2004-05-21 | Galileo Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| FR2875803B1 (fr) | 2004-09-24 | 2006-11-24 | Catalys Sarl | Preparation de composes phenol-amides a proprietes antioxydantes |
| CA2610152C (en) | 2005-06-01 | 2018-04-10 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| ES2823728T3 (es) | 2005-09-15 | 2021-05-10 | Ptc Therapeutics Inc | Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía |
| WO2007095630A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | New ubiquinone analogs and methods of use |
| EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
| WO2008050829A1 (en) | 2006-10-26 | 2008-05-02 | Mitsubishi Gas Chemical Company, Inc. | Method of producing s-(-)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid and product obtained by the method |
| CN101610782A (zh) | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| EP3018122B1 (en) * | 2007-11-06 | 2018-10-10 | BioElectron Technology Corporation | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| WO2009088572A2 (en) | 2008-01-07 | 2009-07-16 | Centocor, Inc. | Method of treating erythropoietin hyporesponsive anemias |
| CA2708961C (en) | 2008-01-08 | 2017-03-28 | Ptc Therapeutics, Inc. | (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| WO2009111543A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments with redox-active therapeutics |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2310038A4 (en) | 2008-05-15 | 2012-03-14 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT |
| CA2724841A1 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| JP5266875B2 (ja) | 2008-05-23 | 2013-08-21 | 三菱瓦斯化学株式会社 | 有機カルボン酸エステルからの光学活性有機カルボン酸の製造方法 |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| US20100029706A1 (en) | 2008-07-30 | 2010-02-04 | Edison Parmaceuticals, Inc. a Delaware Corporation | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| BRPI0918139B1 (pt) | 2008-09-10 | 2024-04-30 | Ptc Therapeutics, Inc | Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CN102264730B (zh) | 2008-10-28 | 2016-04-13 | 爱迪生药物公司 | 用于生产生育三烯酚及衍生物的方法 |
| JP2012525399A (ja) | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| MX2011011310A (es) | 2009-04-28 | 2011-11-18 | Edison Pharmaceuticals Inc | Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas. |
| EP2424360A4 (en) | 2009-04-28 | 2012-10-03 | Ampere Life Sciences Inc | TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES |
| EP2445519A4 (en) | 2009-06-25 | 2012-12-26 | Ampere Life Sciences Inc | TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS USING TOCOTRIENOLS OR TOCOTRIENOLS ENRICHED EXTRACTS |
| SI2470168T1 (en) | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| US8464722B2 (en) | 2010-03-04 | 2013-06-18 | Medline Industries, Inc. | Folded telescopic equipment drape and method of folding and using the same |
| BR112012022634A2 (pt) | 2010-03-09 | 2019-09-24 | Edison Pharmaceuticals Inc | síntese de derivados de alto-tocoferolquinona e métodos de utilização dos mesmos |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| JP2013523816A (ja) | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| CN102985083A (zh) | 2010-04-27 | 2013-03-20 | 爱迪生药物公司 | 治疗眼科疾病的醌类的制剂 |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| US20140031432A1 (en) | 2010-08-06 | 2014-01-30 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006737A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc. | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US10470986B2 (en) | 2013-03-08 | 2019-11-12 | Conopco, Inc. | Resorcinol compounds for dermatological use |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Ptc Therapeutics, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US20160115141A1 (en) | 2013-05-31 | 2016-04-28 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| WO2016100579A1 (en) * | 2014-12-16 | 2016-06-23 | Edison Pharmaceuticals, Inc., | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP2018500317A (ja) | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
| WO2016114860A1 (en) | 2015-01-12 | 2016-07-21 | Edison Pharmaceuticals, Inc. | Quinones for protection against radiation exposure |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| CN113024369A (zh) | 2015-12-17 | 2021-06-25 | Ptc医疗公司 | 用于治疗氧化应急障碍的化合物 |
| WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
| WO2017123820A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Methods for diagnosing and treating oxidative stress disorders using biomarkers |
| US20190241497A1 (en) | 2016-10-28 | 2019-08-08 | Andrew W. Hinman | Methods for analyzing p-hydroquinone levels and ratios |
| WO2018093957A1 (en) | 2016-11-15 | 2018-05-24 | Bioelectron Technology Corporation | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| US20200121618A1 (en) | 2017-04-14 | 2020-04-23 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
-
2015
- 2015-12-16 WO PCT/US2015/066211 patent/WO2016100579A1/en not_active Ceased
- 2015-12-16 ES ES15820968T patent/ES2912585T3/es active Active
- 2015-12-16 SG SG10202003299PA patent/SG10202003299PA/en unknown
- 2015-12-16 NZ NZ733528A patent/NZ733528A/en unknown
- 2015-12-16 CN CN201580076205.0A patent/CN107531616B/zh active Active
- 2015-12-16 BR BR112017012988-4A patent/BR112017012988B1/pt active IP Right Grant
- 2015-12-16 CN CN202210321539.1A patent/CN114702406B/zh active Active
- 2015-12-16 PT PT158209684T patent/PT3233786T/pt unknown
- 2015-12-16 SI SI201531829T patent/SI3233786T1/sl unknown
- 2015-12-16 PL PL15820968T patent/PL3233786T3/pl unknown
- 2015-12-16 MX MX2017008063A patent/MX385049B/es unknown
- 2015-12-16 JP JP2017532088A patent/JP6810692B2/ja active Active
- 2015-12-16 EP EP22155382.9A patent/EP4059922A1/en active Pending
- 2015-12-16 KR KR1020177019399A patent/KR102626895B1/ko active Active
- 2015-12-16 RU RU2017124714A patent/RU2770091C2/ru active
- 2015-12-16 EP EP15820968.4A patent/EP3233786B1/en active Active
- 2015-12-16 CA CA2971252A patent/CA2971252C/en active Active
- 2015-12-16 SG SG11201704968XA patent/SG11201704968XA/en unknown
- 2015-12-16 DK DK15820968.4T patent/DK3233786T3/da active
- 2015-12-16 AU AU2015364640A patent/AU2015364640B2/en active Active
- 2015-12-16 US US15/536,603 patent/US10251847B2/en active Active
- 2015-12-16 HU HUE15820968A patent/HUE058877T2/hu unknown
-
2017
- 2017-06-15 IL IL252953A patent/IL252953A0/en unknown
- 2017-06-16 MX MX2021009340A patent/MX2021009340A/es unknown
- 2017-07-10 ZA ZA2017/04639A patent/ZA201704639B/en unknown
-
2019
- 2019-03-14 US US16/354,070 patent/US10751302B2/en active Active
-
2020
- 2020-03-09 JP JP2020039715A patent/JP7111759B2/ja active Active
- 2020-07-01 US US16/919,044 patent/US11304914B2/en active Active
- 2020-07-24 AU AU2020207880A patent/AU2020207880C1/en active Active
-
2021
- 2021-09-08 JP JP2021146086A patent/JP7277061B2/ja active Active
-
2022
- 2022-03-10 US US17/692,133 patent/US11938101B2/en active Active
- 2022-05-03 AU AU2022202949A patent/AU2022202949B2/en active Active
- 2022-06-10 JP JP2022094160A patent/JP7541546B2/ja active Active
-
2023
- 2023-07-05 US US18/218,575 patent/US20230364029A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021185199A5 (enExample) | ||
| JP2016514697A5 (enExample) | ||
| JP2016515527A5 (enExample) | ||
| CN107207478B (zh) | 苯并咪唑衍生物的新型结晶形式及其制备方法 | |
| JP2015533794A5 (enExample) | ||
| US20180002247A1 (en) | Methods for chiral resolution of trolox | |
| US6262112B1 (en) | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | |
| JP2016515526A5 (enExample) | ||
| JP2016520621A5 (enExample) | ||
| JP2019504018A5 (enExample) | ||
| CA2971252C (en) | POLYMORPHIC AND AMORPHIC FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE | |
| JP2010532382A (ja) | 神経保護のためのｎｍｄａ受容体拮抗薬 | |
| TW201004622A (en) | Aporphine compounds and pharmaceutical use thereof | |
| JP2013133335A (ja) | 環式第３級アミンをアルキル化するための連続方法 | |
| JP6911033B2 (ja) | 極性非プロトン性溶媒を用いたｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法 | |
| WO2016140978A1 (en) | Therapeutic compounds | |
| CN104098548B (zh) | 一种Delafloxacin的精制方法 | |
| CN105085396B (zh) | 用于制备贝达喹啉的中间体及其制备方法和应用 | |
| CN110713443A (zh) | 制备丙二腈肟醚类化合物的方法及中间体化合物 | |
| ES2911289T3 (es) | Procedimiento para preparar L canforsulfonato de voriconazol y voriconazol | |
| US20040102477A1 (en) | Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof | |
| Jafar et al. | Microwave-assisted synthesis and biological activity of ester, carbothioate and carbohydrazide derivative compounds of the drug Ciprofloxacin | |
| AU2019289917B2 (en) | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | |
| CN105348276B (zh) | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 | |
| CN107556266A (zh) | 一种2‑巯基‑4‑取代‑6‑氟苯并噻唑及2‑巯基衍生物的制法、应用 |